When was Gradient Denervation Technologies founded?

Gradient Denervation Technologies was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is Gradient Denervation Technologies located?

Gradient Denervation Technologies is headquartered in Paris, France.

How many employees does Gradient Denervation Technologies have?

As of Aug 31, 2026, the latest employee count at Gradient Denervation Technologies is 18.

Is Gradient Denervation Technologies a funded company?

Gradient Denervation Technologies is a funded company, having raised a total of $19.2M across 3 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 2020.

When was the latest funding round of Gradient Denervation Technologies?

Gradient Denervation Technologies' latest funding was a $***** Series A round on Sep 07, 2023, with participation from 3 investors.

Where does Gradient Denervation Technologies rank among its competitors?

Gradient Denervation Technologies ranks 2nd amongst 3 active competitors, of which 2 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Pulnovo Medical, which secured $100M in Mar, 2025.

Who are the top competitors of Gradient Denervation Technologies?

Gradient Denervation Technologies' top competitors include Pulnovo Medical, Beyond Air and Alterrastherapeutics.com. Among them, Pulnovo Medical secured the most recent funding round in March, 2025.

Gradient Denervation Technologies - 2026 Company Profile, Funding & Competitors

Company Details

Gradient Denervation Technologies provides endovascular, catheter-based technology to treat pulmonary hypertension. The company offers therapy for reducing pulmonary vascular resistance and improving cardiovascular hemodynamics.

Key Metrics

Founded Year

2020

Location

Paris, France

Stage

Series A

Total Funding

$19.2M in 3 rounds

Latest Funding Round

Series A, Sep 07, 2023, $*****

Investors

Sofinnova Partners & 4 more

Ranked

2^nd among 3 active competitors

Employee Count

18 as on Aug 31, 2026

Similar Companies

Pulnovo Medical & 2 more

View Gradient Denervation Technologies' full profile

Gradient Denervation Technologies has raised a total funding of $19.2M over 3 rounds. Its first funding round was on Feb 2020. Its latest funding round was a Series A round on Sep 07, 2023 for $*****. 3 investors participated in its latest round. Gradient Denervation Technologies has 5 institutional investors.

Here is the list of recent funding rounds of Gradient Denervation Technologies:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Sep 07, 2023	4394481	Series A	1692128	2647165	8559722	6746899
2020	8210	Grant (prize money)	9526	6070	6335	EIT Health
Feb 2020	4621232	Seed	9317250	5012185	Sofinnova Partners	2998092

Access funding benchmarks and valuations. Sign up today!

View details of Gradient Denervation Technologies's funding rounds and investors

Gradient Denervation Technologies' employee count trend

Gradient Denervation Technologies has 18 employees as of Aug 26. Here is Gradient Denervation Technologies's employee count trend over the years:

Employee count trend for Gradient Denervation Technologies

Uncover Gradient Denervation Technologies' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Gradient Denervation Technologies include Pulnovo Medical, Beyond Air and Alterrastherapeutics.com. Here is the list of Top 10 competitors of Gradient Denervation Technologies, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Pulnovo Medical 2013, Wuxi (China), Series C	Developer of a medical device for the treatment of pulmonary hypertension	$115M	LAV Asset Management, Qiming Venture Partners ... & 8 others	55/100
2nd	Gradient Denervation Technologies 2020, Paris (France), Series A	Provider of an endovascular, catheter-based technology to treat pulmonary hypertension	$19.2M	Thuja Capital, Sofinnova Partners & 3 others	41/100
3rd	Beyond Air 2021, Garden City (United States), Unfunded	Manufacturer of devices generating inhaled nitric oxide from ambient air	-	-	21/100
4th	Alterrastherapeutics.com 2017, Vienna (Austria), Deadpooled	Developer of therapeutics for pulmonary hypertension	-	BioVaria	14/100